"I am so bothered by the speed by which adults are ready to put chemicals into little girls bodies without a full understanding of what harm those chemicals could cause in the short and long term.
The Texas whistleblower lawsuit against Johnson & Johnson promises to topple the house of cards upon which the public mental health system rests.
"Most off-label use occurs without scientific support."
Two ground breaking legal actions in Texas to rein in out of control psychotropic drug prescribing will have nationwide reverberations.
U.S. State Attorneys General should investigate the fraudulent marketing of the atypical neuroleptic drugs-and FDA's role in helping conceal the truth.
Steven Fiorello, former Chief Pharmacist for the State of Pennsylvania, was arraigned on on Tuesday, November 21, 2006, on Felony and Misdemeanor charges related to his accepting money from drug companies whose drugs he put on the state Formulary.
AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising Wed, 02 Nov 2005 FDA is holding public hearings (Nov 1, 2) Re:Â Direct-to-Consumer Promotion of Medical Products at: National Transportation Safety Board Boardroom and Conference Center 429 L’Enfant Plaza, SW., Washington, DC 2 Time: 9:00 –5:00….
Conflicts of Interest policy – New York Times Sun, 28 Mar 2004 To: ‘Executive-editor@nytimes’; ‘gcollins@nytimes’; ‘arosenthal@nytimes’; ‘pboffey@nytimes’; ‘lchang@nytimes’; ‘oped@nytimes’ Cc: ‘Daniel Okrent’ ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure https://ahrp.org FYI Friday’s New York Times included the following Editor’s Note on the paper’s Op Ed page:…
NYT Editorial: comparing schizophrenia drugs Wed, 21 Sep 2005 Today’s New York Times Editorial acknowledges: “A government-financed study has provided the strongest evidence yet that the system for approving and promoting drugs is badly out of whack. The study compared five drugs used to treat schizophrenia and found that most…
Go Slow on Mental Health Screening: Dr. Karen Effrem responds to New Freedom Commission Chair, Michael Hogan – Wash Times Sun, 31 Oct 2004 A letter to the editor in the Washington Times – Go slow on Mental Health Screening – by AHRP’s newest board member, pediatrician Dr. Karen Effrem,…
Federal Study Finds No Benefit of New Antipsychotic Drugs – WashPost/Wall StreetJ/NY Times Tue, 20 Sep 2005 The findings of a $44 million government sponsored study, CATIE, published in The New England Journal of Medicine, comparing an older generic antipsychotic to four new atypical antipsychotics, undercut the legitimacy of psychiatry’s…
Take Action: Just Say No to Stigmatizing Screening and Unsafe Drugs Tue, 26 Oct 2004 FYI /ACTION! AHRP believes that America’s school children should not be screened and labeled without a guarantee of the proven accuracy of the screening tool, and the proven safety and therapeutic value of the treatment…
